Emergent BioSolutions (EBS) Misses Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.44 -5.43%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of ($0.64), $0.23 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $110 million versus the consensus estimate of $125.8 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Voyager Technologies, Inc. (VOYG) Misses Q3 EPS by 55c; Offer Guidance
- National Presto Indust. (NPK) Reports Q3 EPS of $2.79
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
